Research from Columbia Business School Measures Impact of New Cancer Drugs, Finds Most Significant Reduction in Mortality Rates 5-10 Years After…

Research from Columbia Business School Measures Impact of New Cancer Drugs, Finds Most Significant Reduction in Mortality Rates 5-10 Years After Launch

By a News Reporter-Staff News Editor at Drug Week -- With the World Health Organization estimating the number of cancer diagnoses to rise by about 70 percent over the next two decades, biopharmaceutical companies around the globe are increasing investment in and production of innovative cancer drug treatments. By analyzing both their impact on prolonging life and their cost-effectiveness, groundbreaking research from Columbia Business School looks at the overall impact of recently developed cancer-fighting drugs (see also Columbia Business School).

"Cancer has become a huge focus of pharmaceutical innovation in recent years," said Frank Lichtenberg, author of the study and Courtney C. Brown Professor of Business at Columbia Business School. "While we hear a lot about the cost of drugs, their actual value is less often discussed."

Keywords for this news article include: Cancer, Oncology, Health and Medicine, Columbia Business School.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC